EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Chongqing Xishan Science&Technology Co. Ltd. A (688576) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Chongqing Xishan Science&Technology Co. Ltd. A ¥14.59, price ¥40.36, upside -63.9%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · CN · ISIN CNE100007820

CX Broad data Sep 24, 2026

Chongqing Xishan Science&Technology Co. Ltd. A

688576 · SHG

Weakest SetupStrongly overvalued and low quality.

!Fair value ¥14.59 · Strongly overvalued (−64%)
!Quality 38/100
!Expensive Growth (revenue 3y +9.2 %/yr)
✓Solidly profitable · 13.7% net margin (TTM)
!negative free cash flow
·0.83% dividend yield
!Trails peers (3/12)
!Narrow moat 38/100
!Weak on past: 11 out of 100
!Weak on dividend: 17 out of 100
Watch Chongqing Xishan Science&Technology Co. Ltd. A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥23,143 ¥31.91 Fair Value ¥14.59 Jun 2023 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

40‑month range ¥31.91 – ¥23,143 · fair‑value band ¥11.88 – ¥16.94 · the ¥40.36 price screens above the ¥14.59 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Chongqing Xishan Science&Technology Co. Ltd. A in your weekly email

Every Wednesday you see whether Chongqing Xishan Science&Technology Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Chongqing Xishan Science & Technology Co., Ltd. engages in the research and development, manufacturing, sale, and service of digital minimally invasive surgical equipment and medical consumables in China and internationally.

Show more

Chongqing Xishan Science & Technology Co., Ltd. engages in the research and development, manufacturing, sale, and service of digital minimally invasive surgical equipment and medical consumables in China and internationally. The company offers powered surgical instruments, such as micromotor, handpiece, attachment, shaver, bur, saw blade, and perforator; vacuum-assisted breast biopsy, including control module, handpiece, probe, and canister. It also provides UHD endocsopy systems comprising camera control unit, camera head, light source unit, LCD monitor, transforaminal endoscope, arthroscope, sinoscope, laparoscope, and trolley; ultrasonic bone scalpel systems; RF/HF electrosurgical unit and surgical electrode; and plasma electrosurgical unit and plasma surgical electrode. The company was founded in 1999 and is headquartered in Chongqing, China.

Stock analysis

Chongqing Xishan Science&Technology Co. Ltd. A (688576) currently trades at ¥40.36, while our model-based Fair Value estimate is ¥14.59, implying the stock looks roughly 176.6% overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of ¥17.11 per share, and 0 of the 14 models we run sit above the ¥40.36 price.

Bear case: the Earnings-Based group reads lowest at ¥4.57, and 14 of the 14 models stay below the price. Evidence for this calculation is high.

Scenario range: ¥11.88 (bear) to ¥16.94 (bull), the price of ¥40.36 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Chongqing Xishan Science&Technology Co. Ltd. A reported revenue of 342M CNY in FY2025 versus 209M CNY in FY2021, a compound +13.1%/yr. Reported net income was 51.9M CNY in FY2025, compounding −4.1%/yr from FY2021.

Key figures

Market cap 2.8B CNY (≈ $413M) · P/E ratio 55.3 · P/S ratio 8.39 · EPS (TTM) ¥0.7300 · Dividend yield 0.8% · Net margin 15.2% · Return on equity 2.8% · Return on assets (EBIT) 7.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).

What moves the price

The share trades about 29% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −64%, 688576 screens richer than that median.

Fair Value models

Bear ¥11.88 Fair Value ¥14.59 Bull ¥16.94
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.2893 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Residual Income ¥17.38 ¥16.45 ¥12.78 73
EPV ¥8.04 ¥8.56 ¥8.98 68
ROIC Compounder ¥8.04 ¥8.56 ¥8.98 67
All 14 models by family
Earnings-Based
Graham-Dodd ¥5.22 ¥15.31 ¥20.23 62
Lynch FV ¥3.20 ¥4.57 ¥5.94 58
PEG = 1.0 ¥3.20 ¥4.57 ¥5.94 55
EPV ¥8.04 ¥8.56 ¥8.98 68
Multiples
P/E Multiple ¥12.66 ¥16.88 ¥21.10 63
P/S Multiple ¥9.78 ¥13.05 ¥16.31 58
P/B Multiple ¥9.78 ¥13.05 ¥16.31 55
EV/EBIT ¥11.88 ¥14.41 ¥16.94 63
EV/EBITDA ¥14.52 ¥17.94 ¥21.35 64
EV/Revenue ¥9.70 ¥12.02 ¥14.35 52
Asset-Based
NCAV (Graham) ¥12.77 ¥17.11 ¥25.54 51
Economic Profit
Residual Income ¥17.38 ¥16.45 ¥12.78 73
ROIC Compounder ¥8.04 ¥8.56 ¥8.98 67
Growth Earnings
Growth-Adj P/E ¥10.22 ¥14.59 ¥18.97 65

Open the full fair value analysis →

Notify me when 688576 reaches fair value

Put 688576 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 38/100

Of which business quality 43 · Market factors (momentum, volatility) 37

Profitability 29
Margins and returns on capital today
Quality Growth 25
Are margins and returns improving?
Cashflow 27
Earnings quality: real cash, not paper profit
Fin. Strength 90
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 55
Calm price path (market factor)
Momentum 33
Price trend over the last 3–12 months (market factor)
52W Momentum 23
Distance to the 52-week high (market factor)
Net Issuance 68
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 46/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−5.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.9%
Dividend (yield on the price)0.8%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.27% → 12%

688576 screens 177% overvalued. Compare with Intuitive Surgical, Inc →

Compare Chongqing Xishan Science&Technology Co. Ltd. A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks

Beats the industry median on 3/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Bottom 25%
Fair Value upside −65% · Bottom 25%
Profitability
Return on equity (TTM) 3% · Below median
Return on assets 1% · Bottom 25%
Net margin (TTM) 14% · Above median
Operating margin (TTM) 7% · Below median
Growth and dividend
Revenue growth 9% · Above median
Dividend yield (TTM) 0.8% · Below median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 55.3× · Priciest 25%
P/B 1.60× · Cheaper than median
P/S (TTM) 7.95× · Priciest 25%
EV/EBITDA 50.3× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)45 · sector 31
PAST (return on equity)11 · sector 25
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)17 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $402.09 $353.38 −12%
EssilorLuxottica Société anonyme EL €144.50 €158.95 +10%
Medline Inc MDLN $34.43 $30.15 −12%
Becton, Dickinson and Company BDX $183.00 $103.53 −43%
Alcon Inc ALC $65.59 $39.78 −39%
ResMed Inc RMD A$31.61 A$34.77 +10%
West Pharmaceutical Services, Inc WST $371.09 $137.28 −63%
Sartorius Stedim Biotech S.A DIM €206.40 €54.82 −73%
Straumann Holding STMN CHF 97.86 CHF 45.50 −54%
Solventum Corporation SOLV $88.75 $130.51 +47%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Chongqing Xishan Science&Technology Co. Ltd. A · Fair Value
¥14.59 −177%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Chongqing Xishan Science&Technology Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688576

Frequently asked questions

Is Chongqing Xishan Science&Technology Co. Ltd. A (688576) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥14.59 versus a price of ¥40.36, about −64% upside (overvalued).
What is the fair value of 688576?
Our model-based fair value for Chongqing Xishan Science&Technology Co. Ltd. A is ¥14.59 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥40.36.
What is the quality score of 688576?
Chongqing Xishan Science&Technology Co. Ltd. A has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Chongqing Xishan Science&Technology Co. Ltd. A (688576)?
Our model-based price target is the fair value of ¥14.59 (as of Sep 24, 2026) from 14 valuation models. Cautious scenario ¥11.88, optimistic scenario ¥16.94. It is a calculation from audited fundamentals, not an analyst target.
What is the Chongqing Xishan Science&Technology Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥14.59, about −64% upside versus a price of ¥40.36 (overvalued). Cautious scenario ¥11.88, optimistic scenario ¥16.94. The calculation is refreshed regularly with new filings.
What is the revenue of Chongqing Xishan Science&Technology Co. Ltd. A (688576)?
Chongqing Xishan Science&Technology Co. Ltd. A reported trailing-twelve-month revenue of about 348M CNY (latest available figure, as of Sep 24, 2026).
Does Chongqing Xishan Science&Technology Co. Ltd. A pay a dividend?
Chongqing Xishan Science&Technology Co. Ltd. A currently shows a dividend yield of about 0.83% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Chongqing Xishan Science&Technology Co. Ltd. A (688576)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Chongqing Xishan Science&Technology Co. Ltd. A it is ¥14.59 per share (as of Sep 24, 2026), against a price of ¥40.36. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Chongqing Xishan Science&Technology Co. Ltd. A stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 688576 trades above its calculated fair value: price ¥40.36, fair value ¥14.59, a gap of about −64% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688576?
No. The price is what the market pays today (¥40.36); the fair value is what the company's own numbers justify (¥14.59). For Chongqing Xishan Science&Technology Co. Ltd. A the two are ¥25.77 per share apart. That gap is exactly why we show both numbers side by side.
How much is Chongqing Xishan Science&Technology Co. Ltd. A worth?
The market values Chongqing Xishan Science&Technology Co. Ltd. A at about 2.8B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥40.36; our models calculate a fair value of ¥14.59 per share.
What do the bullish and bearish scenarios say about 688576?
Our models span a range for Chongqing Xishan Science&Technology Co. Ltd. A: cautious scenario ¥11.88, base ¥14.59, optimistic ¥16.94 per share (as of Sep 24, 2026, price ¥40.36). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688576?
Chongqing Xishan Science&Technology Co. Ltd. A trades at a price-to-earnings ratio of 55.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥14.59 is built from several models across several years. Other multiples: P/B 1.6, P/S 8.0, EV/EBITDA 50.3.
How solid is the balance sheet of Chongqing Xishan Science&Technology Co. Ltd. A (688576)?
Balance-sheet figures for Chongqing Xishan Science&Technology Co. Ltd. A (as of Sep 24, 2026): return on equity 2.8%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is 688576 from its 52-week high?
Chongqing Xishan Science&Technology Co. Ltd. A trades at ¥40.36, about 29% below its 52-week high of ¥57.11 and 13% above the low of ¥35.57 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of ¥14.59 is for.
Which stocks are comparable to Chongqing Xishan Science&Technology Co. Ltd. A?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Chongqing Xishan Science&Technology Co. Ltd. A stock attractive at the current price?
The data as of Sep 24, 2026: price ¥40.36, calculated fair value ¥14.59 (−64%), Quality Score 38/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688576 calculated?
We run Chongqing Xishan Science&Technology Co. Ltd. A through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥14.59, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Chongqing Xishan Science&Technology Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Chongqing Xishan Science&Technology Co. Ltd. A (688576)?
The closing price on Sep 24, 2026 was ¥40.36. Our model-based fair value is ¥14.59, about −64% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Chongqing Xishan Science&Technology Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥16.94). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts.

Key figures of Chongqing Xishan Science&Technology Co. Ltd. A

How large is the market capitalisation of Chongqing Xishan Science&Technology Co. Ltd. A (688576)?
The market capitalisation of Chongqing Xishan Science&Technology Co. Ltd. A is 2.8B CNY (≈ $413M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Chongqing Xishan Science&Technology Co. Ltd. A (688576)?
The price-to-sales ratio of Chongqing Xishan Science&Technology Co. Ltd. A is 8.39 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Chongqing Xishan Science&Technology Co. Ltd. A (688576)?
Earnings per share at Chongqing Xishan Science&Technology Co. Ltd. A are ¥0.7300 (price ÷ EPS = P/E 55.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Chongqing Xishan Science&Technology Co. Ltd. A (688576)?
The dividend yield of Chongqing Xishan Science&Technology Co. Ltd. A is 0.8% (payout 46.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Chongqing Xishan Science&Technology Co. Ltd. A (688576)?
The net margin of Chongqing Xishan Science&Technology Co. Ltd. A is 15.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Chongqing Xishan Science&Technology Co. Ltd. A (688576)?
The return on equity (ROE) of Chongqing Xishan Science&Technology Co. Ltd. A is 2.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Chongqing Xishan Science&Technology Co. Ltd. A (688576)?
On an EBIT basis the return on assets of Chongqing Xishan Science&Technology Co. Ltd. A is 7.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Chongqing Xishan Science&Technology Co. Ltd. A (688576)?
The operating margin of Chongqing Xishan Science&Technology Co. Ltd. A is 7.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Chongqing Xishan Science&Technology Co. Ltd. A (688576)?
Revenue at Chongqing Xishan Science&Technology Co. Ltd. A is growing +9.0% versus a year earlier (3y avg +9.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Chongqing Xishan Science&Technology Co. Ltd. A (688576)?
Earnings per share at Chongqing Xishan Science&Technology Co. Ltd. A are growing −30.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Chongqing Xishan Science&Technology Co. Ltd. A (688576) generate?
The free cash flow of Chongqing Xishan Science&Technology Co. Ltd. A is −36.0M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Chongqing Xishan Science&Technology Co. Ltd. A in the live analysis

One click puts Chongqing Xishan Science&Technology Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.